Index to Volume 9

Author Index

– A –

Abou-Shala N: *see* Self TH, et al, 260
Ackerman BH, Olsen KM, Kennedy EE, Taylor EH, Chen BH, Jordan D. Ackerman DJ: Comparison of disposition values obtained by two assay methods for quinidine gluconate in patients with ventricular tachycardia, 220
Ackerman DJ: *see* Ackerman BH, et al, 220
Amarshi N: *see* Self TH, et al, 260
Ameer B, Burlingame MB, Harman EM: Systemic absorption of topical lidocaine in elderly and young adults undergoing bronchoscopy, 74
Applegate WB: *see* Sirgo MA, et al, 295

– B –

Bauman JL: Results of the CAST . . . what did we catch?, 267
Bauman JL: *see* McCollam PL, et al, 144
Bauman JL: *see* Majerus TC, et al, 245
Beaver WT: *see* Forbes JA, et al, 66
Beaver WT: *see* Forbes JA, et al, 322
Beckman KJ: *see* McCollam PL, et al, 144
Bedell GN: *see* Hall TG, et al, 232
Berry AJ: *see* Sahai J, et al, 29
Bertch KE: *see* Willett MS, et al, 45
Bertch KE: *see* Gubbins PO, et al, 285
Bhatt-Mehta V, Nahata MC: Dopamine and dobutamine in pediatric therapy, 303
Blum RA: *see* Zokufa HZ, et al, 10
Bottorff MB, Lalonde RL, Kazierad DJ, Hoon TJ, Tsiu SJ, Mirvis DM: The effects of encainide vs diltiazem on the oxidative metabolic pathways of antipyrine, 315
Boyd BK: *see* Sirgo MA, et al, 295
Brater DC: Commentary on lisinopril, 128
Bryson JC: *see* Kirby MG, et al, 226
Burchfield WH: *see* Forbes JA, et al, 322
Burgess ED, Duff HJ: Hemodialysis removal of propafenone, 331
Burlingame MB: *see* Ameer B, et al, 74
Burns-Schaiff RA: *see* Hall TG, et al, 232
Bussey HI, Rospond RM, Quandt CM, Clark GM: The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic, 214
Bussey HI: Can we preserve the passion for practice in clinical pharmacy . . . please?, 114
Bussey HI: Commentary on lisinopril, 129
Bussey HI: *see* Rospond RM, et al: 207
Butterworth GA: *see* Forbes JA, et al, 322

– C –

Caldwell JW: *see* Grasela TH, et al, 158
Carlson JD: *see* Greene JG, et al, 34
Carr DS: *see* Noble TA, et al, 386
Carter BL, Gersema LM, Williams GO, Schabold K: Once-daily propranolol for hypertension: a comparison of regular-release, long-acting, and generic formulations, 17
Chase SL, Sutton JD: Lisinopril: a new angiotensin-converting enzyme inhibitor, 120
Chase SL: *see* Flaharty KK, et al, 39
Chen BH: *see* Ackerman BH, et al, 220
Clark GM: *see* Bussey HI, et al, 214
Clark GM: *see* Rospond RM, et al: 207
Crossley KB: *see* Zohufa HZ, et al, 10

– D –

Danziger LH: *see* Majerus TC, et al, 245
Dasta JF: *see* Majerus TC, et al, 245
Decker EL: Meta-analysis: whither narrative review? (commentary), 281
Duff HJ: *see* Burgess ED, et al, 331
Dukes GE: *see* Kirby MG, et al, 226
Dushay ME, Johnson CE: Management of allergic rhinitis: focus on intranasal agents, 338

– E –

Ellis RF: *see* Self TH, et al, 260
Ereshefsky L: *see* Willett MS, et al, 45
Evans WE: Who said practice makes perfect?, 113

– F –

Ferguson RK: *see* Ujhelyi MR, et al, 351
Figge HL: Nicotinic acid in the treatment of lipid disorders (commentary), 271
Fischer JH: *see* Zokufa HZ, et al, 10
Flaharty KK, Chase SL, Yaghsezian HM, Rubin R: Hepatotoxicity associated with amiodarone therapy, 39
Forbes JA, Butterworth GA, Burchfield WH, Yorio CC, Selinger LR, Rosenmertz SK, Beaver WT: Evaluation of flurbiprofen, acetaminophen, an acetaminophen-codeine combination, and placebo in postoperative oral surgery pain, 322
Forbes JA, Yorio CC, Selinger LR, Rosenmertz SK, Beaver WT: An evaluation of flurbiprofen, aspirin, and placebo in postoperative oral surgery pain, 66
Frost RW: *see* Nix DE, et al, 377
Fuerst RH: *see* Graves NM, et al, 372

– G –

Gersema LM: *see* Carter BL, et al, 17
Goldstein HR: *see* Nix DE, et al, 377
Gonzalez MF: *see* Noble TA, et al, 386
Grasela TH, Walawander CA, Welage LS, Wing PE, Scarafoni DJ, Caldwell JW, Noguchi JK, Schentag JJ: Prospective surveillance of antibiotic-associated coagulopathy in 970 patients, 158
Graves NM, Ludden TM, Holmes GB, Fuerst RH, Leppik IE: Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials, 372
Graves T, Hooks MA: Drug-induced toxicities associated with high-dose cytosine arabinoside infusions, 23
Green JA, Munger MA: On the fringes, 95
Greene JG, Pucino F, Carlson JD, Storsved M, Strommen GL: Effects of alprazolam on respiratory drive, anxiety,

and dyspnea in chronic airflow obstruction: a case study, 34
Greer C: Pakistani spice merchants (photo), 28
Gubbins PO, Bertch KE: Drug absorption in gastrointestinal disease and surgery, 285
Guthrie SK: The treatment of alcohol withdrawal, 131

– H –

Haas JL, Shaefer MS, Miwa LJ, Wood RP, Shaw BW: Prolonged paralysis associated with long-term pancuronium use, 154
Hall TG, Kasik JE, Bedell GN, Burns-Schaiff RA: The efficacy of inhaled beclomethasone in chronic obstructive airway disease, 232
Hameroff SR: *see* Plezia PM, et al, 2
Handy L: *see* Nix DE, et al, 377
Hariman RJ: *see* McCollam PL, et al, 144
Harman EM: *see* Ameer B, et al, 74
Heim-Duthoy KL: *see* Tortorice KL, et al, 363
Heizer WD: *see* Kirby MG, et al, 226
Holmes GB: *see* Graves NM, et al, 372
Hooks MA: *see* Graves T, et al, 23
Hoon TJ: *see* Bottorff MB, et al, 315
Hume AL, Murphy JL, Lauerman SE: Angiotensin-converting enzyme inhibitor-induced cough, 88
Hunter JR: *see* Jick H, et al, 91

– J –

Jeffries S: A table is a table is not a list, 65
Jeffries S: Neologisms, the syndrome, 203; Neologisms, acronyms, 273; Neologisms, sexist language, 337
Jeffries S: Often-ness, 1
Jeffries S: There is, is there?, 119
Jick H, Jick SS, Hunter JR, Walker AM: Follow-up study of tolmetin users, 91
Jick H, Jick SS, Walker AM, Stergachis A: A comparison of wax matrix and microencapsulated potassium chloride in relation to upper GI illness requiring hospitalization, 204
Jick S: *see* Jick H, et al, 91
Jick SS: *see* Jick H, et al, 204
Johnson CE: *see* Dushay ME, et al, 338
Johnson JA: *see* Prince RA, et al, 240
Jordan D: *see* Ackerman BH, et al, 220
Just PM: The positive association of cough with angiotensin-converting enzyme inhibitors, 82

– K –

Kasik JE: *see* Hall TG, et al, 232
Kazierad DJ: *see* Bottorff MB, et al, 315
Kennedy EE: *see* Ackerman BH, et al, 220
Kirby MG, Dukes GE, Heizer WD, Bryson JC, Powell JR: Effect of metoclopramide, bethanechol, and loperamide on gastric residence time, gastric emptying, and mouth-to-cecum transit time, 226
Kramer TH: *see* Plezia PM, et al, 2

– L –

Labreche DG: Nicotinic acid in the treatment of lipid disorders (commentary), 270
Labreche DG: The rise and fall of the apothecary: will history repeat itself?, 105
Lalonde RL: *see* Bottorff MB, et al, 315
Lauerman SE: *see* Hume AL, et al, 88
Leppik IE: *see* Graves NM, et al, 372
Linford J: *see* Plezia PM, et al, 2
Ludden TM: *see* Graves NM, et al, 372
Lundergan MK: *see* Shirley HH, et al, 165

– M –

Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR, Jr: Dobutamine: ten years later, 245
McCollam PL, Parker RB, Beckman KJ, Hariman RJ, Bauman JL: Proarrhythmia: a paradoxic response to antiarrhythmic agents, 144
Melby MJ: Diagnosis and therapy of acute adrenal insufficiency (commentary), 269
Michael KA, Mohler JL: Diagnosis and therapy of acute adrenal insufficiency (commentary), 269
Mirvis DM: *see* Bottorff MB, et al, 315
Miwa LJ: *see* Haas JL, et al, 154
Mohler JL: *see* Michael KA, et al, 269
Munger MA: *see* Green JA, et al, 95
Murphy JL: *see* Hume AL, et al, 88

– N –

Nahata MC: *see* Bhatt-Mehta V, et al, 303
Nix DE, Watson WA, Handy L, Frost RW, Rescott DL, Goldstein HR: The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin, 377
Noble TA, Carr DS, Gonzalez MF: Use of trypsin, peru balsam, and castor oil spray on the oral mucosa: case report and review of the literature, 386
Noguchi JK: *see* Grasela TH, et al, 158

– O –

Olsen KM: *see* Ackerman BH, et al, 220

– P –

Parker RB: *see* McCollam PL, et al, 144
Plezia PM, Kramer TH, Linford J, Hameroff SR: Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation, 2
Polk R: Meta-analysis: whither narrative review? (commentary), 282
Post D: Eruption of Mt. Kilauea, Hawaii (photo), 336
Powell JR: *see* Kirby MG, et al, 226
Prince RA, Johnson JA, Weinberger MM: Influence of endotoxin-induced fever on the pharmacokinetics of theophylline in the rabbit model, 240
Pucino F: *see* Greene JG, et al, 34

– Q –

Quandt CM: *see* Rospond RM, et al: 207
Quandt CM: *see* Bussey HI, et al, 214

– R –

Rescott DL: *see* Nix DE, et al, 377
Rich DS: *see* Willett MS, et al, 45
Riff LJ: *see* Zokufa HZ, et al, 10

Rodvold KA: *see* Zokufa HZ, et al, 10
Rosenmertz SK: *see* Forbes JA, et al, 66
Rosenmertz SK: *see* Forbes JA, et al, 322
Rospond RM, Quandt CM, Clark GM, Bussey HI: Evaluation of factors associated with stability of anticoagulation therapy, 207
Respond RM: *see* Bussey HI, et al, 214
Rotschafer JC: *see* Zokufa HZ, et al, 10
Rubin R: *see* Flaharty KK, et al, 39
Ruffolo RR, Jr: *see* Majerus TC, et al, 245

– S –

Sahai J, Berry AJ: Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with AIDS: a preliminary review, 29
Scarafoni DJ: *see* Grasela TH, et al, 158
Scavone JM: Pharmacy and research: which side of the door are we on?, 111
Schabold K: *see* Carter BL, et al, 17
Schallinger LE, Uden DL: The effect of paraldehyde on intravenous tubing sets, 381
Scheife RT: Bhutanese school children (photo), 272
Scheife RT: Hong Kong boat people (photo), 118
Scheife RT: Marketplace, Thimphu, Bhutan (photo), 157
Schentag JJ: *see* Grasela TH, et al, 158
Self TH, Ellis RF, Abou-Shala N, Amarshi N: Is theophylline use justified in acute exacerbations of asthma?, 260
Selinger LR: *see* Forbes JA, et al, 66
Selinger LR: *see* Forbes JA, et al, 322
Shaefer MS: *see* Haas JL, et al, 154
Shaw BW: *see* Haas JL, et al, 154
Shirley HH, Lundergan MK, Williams HJ, Sprunace SL: Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma, 165
Sirgo MA, Boyd BK, Applegate WB: Treatment of hypertension in the elderly with labetalol, 295
Sprunace SL: *see* Shirley HH, et al, 165
Stergachis A: *see* Jick H, et al, 204
Storsved M: *see* Greene JG, et al, 34
Strommen GL: *see* Greene JG, et al, 34
Sutton JD: *see* Chase SL, et al, 120

– T –

Taylor EH: *see* Ackerman BH, et al, 220
Teagarden JR: Meta-analysis: whither narrative review?, 274
Tortorice KL, Heim-Duthoy KL: Clinical features and treatment of Lyme disease, 363
Tsiu SJ: *see* Bottorff MB, et al, 315

– U –

Uden DK: *see* Schallinger LE, et al, 381
Ujhelyi MR, Ferguson RK, Vlasses PH: Angiotensin-converting enzyme inhibitors: mechanistic controversies, 351

– V –

Vlasses PH: *see* Ujhelyi MR, et al, 351

– W –

Walawander CA: *see* Grasela TH, et al, 158
Walker AM: *see* Jick H, et al, 91
Walker AM: *see* Jick H, et al, 204
Watson WA: *see* Nix DE, et al, 377
Weinberger MM: *see* Prince RA, et al, 240
Welage LS: *see* Grasela TH, et al, 158
Willett MS, Bertch KE, Rich DS, Ereshefsky L: Prospectus on the economic value of clinical pharmacy services: A Position Statement of the American College of Clinical Pharmacy, 45
Williams GO: *see* Carter BL, et al, 17
Williams HJ: *see* Shirley HH, et al, 165
Williams NR: Legal perspectives relevant to expanded pharmacy practice, 99
Wing PE: *see* Grasela TH, et al, 158
Wood RP: *see* Haas JL, et al, 154

– Y –

Yaghsezin HM: *see* Flaharty KK, et al, 39
Yorio CC: *see* Forbes JA, et al, 66
Yorio CC: *see* Forbes JA, et al, 322

– Z –

Zokufa HZ, Rodvold KA, Blum RA, Riff LJ, Fischer JH, Crossley KB, Rotschafer JC: Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients, 10

Subject Index

– A –

Abstracts of 10th annual ACCP meeting, 169
ACCP Position Statement, economic value of clinical pharmacy services, 45
ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors
Acetaminophen vs flurbiprofen, acetaminophen-codeine, and placebo in postoperative oral surgery pain, 322
Adrenal insufficiency, acute, diagnosis and treatment of (commentary), 269
AIDS, treatment of P. carinii pneumonia in patients with, 29
Alcohol withdrawal, treatment of, 131
Allergic rhinitis, management of, with focus on intranasal agents, 338
Alprazolam, effect on respiratory drive, anxiety, and dyspnea (case study), 34
Amiodarone, hepatotoxicity associated with, 39
Angiotensin-converting enzyme inhibitors, association of cough with (case report), 88
Angiotensin-converting enzyme inhibitors, mechanistic controversies, 351
Angiotensin-converting enzyme inhibitors, positive association of cough with, 82
Antiarrhythmic agents, proarrhythmia as a paradoxic response to, 144
Antibiotic-associated coagulopathy, surveillance of, 158
Anticoagulation therapy, factors associated with stability of, 207; safety and effectiveness of long-term therapy with, 214
Apothecary, the rise and fall of, commentary on the profession of pharmacy, 105
ARA-C, *see* Cytosine arabinoside, toxicities associates with high-dose, 23
Asthma, is the use of theophylline justified in the treatment of acute exacerbations of?, 260

– B –

Beclomethasone, inhaled, efficacy of in chronic obstructive airway disease, 232
Bethanechol, metoclopramide, and loperamide; effects of on gastric residence time, gastric emptying, and mouth-to-cecum transit time, 226
Bronchoscopy, systemic absorption of lidocaine in elderly and young adults during, 74

– C –

CAST, results of (commentary), 267
Castor oil, peru balsam, and trypsin; use on the oral mucosa (case and literature review), 386
Ciprofloxacin, effect of sucralfate pretreatment on pharmacokinetics of, 377
Clinical pharmacy services, economic value of, ACCP Position Statement, 45
Coagulopathy, antibiotic-associated, surveillance of, 158
Cough, association with angiotensin-converting enzyme inhibitors (case report), 88
Cough, positive association with angiotensin-converting enzyme inhibitors, 82
Cytosine arabinoside, toxicities associated with high-dose, 23

– D –

Diltiazem vs encainide, effects on the oxidative metabolic pathways of antipyrine, 315
Dimethyl sulfoxide, lack of ocular changes in scleroderma therapy, 165
DMSO, *see* dimethyl sulfoxide, 165
Dobutamine and dopamine, use in pediatric patients, 303
Dobutamine, ten year evaluation of, 245
Dopamine and dobutamine, use in pediatric patients, 303
Drug absorption, effect of gastrointestinal disease and surgery on, 285

– E –

Economic value of clinical pharmacy services, ACCP Position Statement, 45
Eflornithine, for treatment of P. carinii pneumonia in patients with AIDS, 29
Encainide vs diltiazem, effects on the oxidative metabolic pathways of antipyrine, 315
Ethanol withdrawal, *see* alcohol withdrawal, treatment of, 131

– F –

Felbamate, pharmacokinetics of, application of mixed-effect modeling to clinical trials, 372
Fentanyl, transdermal, pharmacokinetics and clinical evaluation, 2
Fever, endotoxin-induced, effect on pharmacokinetics of theophylline in rabbits, 240
Flurbiprofen vs acetaminophen, acetaminophen-codeine, and placebo in postoperative oral surgery pain, 322
Flurbiprofen vs aspirin and placebo, in postoperative oral surgery pain, 66
Frequency, editorial on often-ness, 1

– G –

Gastrointestinal disease and surgery, effect of on drug absorption, 285
Gastrointestinal illness, relation to wax matrix vs microencapsulated potassium chloride, 204

– H –

Hemodialysis, to remove propafenone, 331
Hepatotoxicity, associated with amiodarone therapy, 39
Hypertension in the elderly, treatment with labetalol, 295
Hypertension, once-daily treatment with propranolol, comparison of regular vs long-acting vs generic, 17

– I –

Incidence, editorial on often-ness, 1
Intranasal agents, use in management of allergic rhinitis, 338

– L –

Labetalol, treatment of hypertension in the elderly with, 295
Legal perspectives relevant to expanded pharmacy practice, 99
Lidocaine, systemic absorption of in elderly and young adults, 74
Lisinopril, chemistry, pharmacodynamics, 121; pharmacokinetics, clinical trials, 122; adverse effects, 125; place in therapy, 126; commentaries on, 128
Loperamide, metoclopramide, and bethanechol; effects of on gastric residence time, gastric emptying, and mouth-to-cecum transit time, 226
Lyme disease, clinical features and treatment of, 363

– M –

Meta-analysis, review and commentaries, 274
Metoclopramide, bethanechol, and loperamide; effects of on gastric residence time, gastric emptying, and mouth-to-cecum transit time, 226
Mixed-effect modeling, application to clinical trials of felbamate, 372

– N –

Neologisms, the syndrome, 203; Acronyms, 273; sexist language, 337
Nicotinic acid, in the treatment of lipid disorders (commentary), 270

– O –

Ocular changes, lack of with DMSO therapy of scleroderma, 165
Often-ness (Editorial), 1
On the fringes, commentary on the profession of pharmacy, 95

– P –

Pancuronium, prolonged paralysis associated with (case report), 154
Paraldehyde, effect on intravenous tubing sets, 381
Paralysis, prolonged, associated with pancuronium (case report), 154
Pediatrics, use of dopamine and dobutamine in, 303
Peru balsam, trypsin, and castor oil; use on the oral mucosa (case and literature review), 386
Pharmacy, commentaries on the profession of: "On the fringes", 95; "Legal perspectives relevant to expanded practice", 99; "The rise and fall of the apothecary", 105; "Pharmacy research, which side of the door are we on?", 111; "Who said practice makes perfect?", 113; "Can we preserve the passion for practice in clinical pharmacy?", 114
Plastic intravenous tubing sets, effect of paraldehyde on, 381
Pneumocystis carinii, treatment with eflornithine in patients with AIDS, 29
Potassium chloride, comparison of wax-matrix and microencapsulated preparations in relation to upper GI illness, 204
Prevalence, editorial on often-ness, 1
Proarrhythmia: a paradoxic response to antiarrhythmic agents, 144
Propafenone, hemodialysis removal of, 331
Propranolol, once-daily treatment of hypertension, comparison of regular vs long-acting vs generic, 17

– Q –

Quinidine gluconate, comparison of disposition values obtained by two assay methods, 220

– R –

Research, pharmacy and (commentaries), 95, 99, 105, 111
Respiratory drive, alprazolam effect on (case study), 34

– S –

Statistics, meta-analysis, review of and commentaries, 274
Sucralfate, effect of pretreatment with, on pharmacokinetics of ciprofloxacin, 377
Surgery and gastrointestinal disease, effect of on drug absorption, 285

– T –

Tables, use in scientific literature, 65
Theophylline, influence of endotoxin-induced fever on the pharmacokinetics of in rabbits, 240
Theophylline, is its use justified in acute exacerbations of asthma?, 260
Tolmetin, follow-up study of users, 91
Transdermal fentanyl, pharmacokinetics and clinical evaluation, 2
Trypsin, peru balsam, an castor oil; use on the oral mucosa (case and literature review), 386

– V –

Vancomycin, simulation of peak and trough concentrations using 5 dosing methods, 10

– W –

Warfarin, factors associated with stability of therapy with, 207
Warfarin, safety and effectiveness of long-term therapy with, 214